Governmental authority status supports construction-service exemption, while pre-cutoff contract and stamp-duty compliance requires verification on re...
Automated Free Sale and Commerce Certificates enable paperless processing while retaining risk-based manual verification for selected exporter applica...
Employee stock-shortage penalties do not constitute consideration for services, preventing GST collection under Schedule II in employment relationship...
Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs.
Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
of 4828 
Join Channel 
